The Tissue-Associated Microbiota in Colorectal Cancer: A Systematic Review
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Eligibility Criteria
2.2. Information Sources and Search Strategy
2.3. Selection Process
2.4. Data Collection Process and Data Items
2.5. Methodological Quality
2.6. Qualitative Synthesis of Microbial Taxonomy Results
3. Results
3.1. Literature Search and Selection of Eligible Studies
3.2. Population Characteristics and Quality Assessment of the Included Studies
3.3. Microbial Diversity Findings
3.4. Microbial Taxonomy Findings
3.5. Microbiota and Clinicopathological Features
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Ferlay, J.; Ervik, M.; Lam, F.; Colombet, M.; Mery, L.; Piñeros, M.; Znaor, A.; Soerjomataram, I.; Bray, F. Global Cancer Observatory: Cancer Today. Available online: https://gco.iarc.fr/today (accessed on 4 January 2022).
- Xie, Y.H.; Chen, Y.X.; Fang, J.Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther. 2020, 5, 22. [Google Scholar] [CrossRef] [PubMed]
- Survival Rates for Colorectal Cancer. Available online: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html (accessed on 28 December 2021).
- Kuipers, E.J.; Grady, W.M.; Lieberman, D.; Seufferlein, T.; Sung, J.J.; Boelens, P.G.; van de Velde, C.J.; Watanabe, T. Colorectal cancer. Nat. Rev. Dis. Primers 2015, 1, 15065. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Müller, M.F.; Ibrahim, A.E.; Arends, M.J. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016, 469, 125–134. [Google Scholar] [CrossRef] [Green Version]
- Fearon, E.R. Molecular Genetics of Colorectal Cancer. Annu. Rev. Pathol. Mech. Dis. 2011, 6, 479–507. [Google Scholar] [CrossRef] [PubMed]
- Hughes, L.A.E.; Simons, C.; van den Brandt, P.A.; van Engeland, M.; Weijenberg, M.P. Lifestyle, Diet, and Colorectal Cancer Risk According to (Epi)genetic Instability: Current Evidence and Future Directions of Molecular Pathological Epidemiology. Curr. Colorectal Cancer Rep. 2017, 13, 455–469. [Google Scholar] [CrossRef] [Green Version]
- Cho, I.; Blaser, M.J. The human microbiome: At the interface of health and disease. Nat. Rev. Genet. 2012, 13, 260–270. [Google Scholar] [CrossRef] [Green Version]
- Gilbert, J.A.; Blaser, M.J.; Caporaso, J.G.; Jansson, J.K.; Lynch, S.V.; Knight, R. Current understanding of the human microbiome. Nat. Med. 2018, 24, 392–400. [Google Scholar] [CrossRef]
- Allen, J.; Sears, C.L. Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: Contributions to colorectal cancer development. Genome Med. 2019, 11, 11. [Google Scholar] [CrossRef] [Green Version]
- Ferreira, R.M.; Pereira-Marques, J.; Pinto-Ribeiro, I.; Costa, J.L.; Carneiro, F.; Machado, J.C.; Figueiredo, C. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 2018, 67, 226–236. [Google Scholar] [CrossRef] [Green Version]
- Tilg, H.; Adolph, T.E.; Gerner, R.R.; Moschen, A.R. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell 2018, 33, 954–964. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kostic, A.D.; Chun, E.; Robertson, L.; Glickman, J.N.; Gallini, C.A.; Michaud, M.; Clancy, T.E.; Chung, D.C.; Lochhead, P.; Hold, G.L.; et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013, 14, 207–215. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goodwin, A.C.; Destefano Shields, C.E.; Wu, S.; Huso, D.L.; Wu, X.; Murray-Stewart, T.R.; Hacker-Prietz, A.; Rabizadeh, S.; Woster, P.M.; Sears, C.L.; et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl. Acad. Sci. USA 2011, 108, 15354–15359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arthur, J.C.; Perez-Chanona, E.; Mühlbauer, M.; Tomkovich, S.; Uronis, J.M.; Fan, T.J.; Campbell, B.J.; Abujamel, T.; Dogan, B.; Rogers, A.B.; et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338, 120–123. [Google Scholar] [CrossRef] [Green Version]
- Castellarin, M.; Warren, R.L.; Freeman, J.D.; Dreolini, L.; Krzywinski, M.; Strauss, J.; Barnes, R.; Watson, P.; Allen-Vercoe, E.; Moore, R.A.; et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012, 22, 299–306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bullman, S.; Pedamallu, C.S.; Sicinska, E.; Clancy, T.E.; Zhang, X.; Cai, D.; Neuberg, D.; Huang, K.; Guevara, F.; Nelson, T. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017, 358, 1443–1448. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marchesi, J.R.; Dutilh, B.E.; Hall, N.; Peters, W.H.; Roelofs, R.; Boleij, A.; Tjalsma, H. Towards the human colorectal cancer microbiome. PLoS ONE 2011, 6, e20447. [Google Scholar] [CrossRef] [Green Version]
- Dai, Z.; Coker, O.O.; Nakatsu, G.; Wu, W.K.; Zhao, L.; Chen, Z.; Chan, F.K.; Kristiansen, K.; Sung, J.J.; Wong, S.H. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome 2018, 6, 1–12. [Google Scholar] [CrossRef]
- Baxter, N.T.; Ruffin, M.T.t.; Rogers, M.A.; Schloss, P.D. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med. 2016, 8, 37. [Google Scholar] [CrossRef] [Green Version]
- Young, C.; Wood, H.M.; Fuentes Balaguer, A.; Bottomley, D.; Gallop, N.; Wilkinson, L.; Benton, S.C.; Brealey, M.; John, C.; Burtonwood, C.; et al. Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy. Clin. Cancer Res. 2021, 27, 2246–2254. [Google Scholar] [CrossRef]
- Parthasarathy, G.; Chen, J.; Chen, X.; Chia, N.; O’Connor, H.M.; Wolf, P.G.; Gaskins, H.R.; Bharucha, A.E. Relationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation. Gastroenterology 2016, 150, 367–379.e361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zoetendal, E.G.; von Wright, A.; Vilpponen-Salmela, T.; Ben-Amor, K.; Akkermans, A.D.; de Vos, W.M. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl. Environ. Microbiol. 2002, 68, 3401–3407. [Google Scholar] [CrossRef] [Green Version]
- Brennan, C.A.; Garrett, W.S. Gut Microbiota, Inflammation, and Colorectal Cancer. Annu. Rev. Microbiol. 2016, 70, 395–411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amitay, E.L.; Krilaviciute, A.; Brenner, H. Systematic review: Gut microbiota in fecal samples and detection of colorectal neoplasms. Gut Microbes 2018, 9, 293–307. [Google Scholar] [CrossRef] [Green Version]
- Wirbel, J.; Pyl, P.T.; Kartal, E.; Zych, K.; Kashani, A.; Milanese, A.; Fleck, J.S.; Voigt, A.Y.; Palleja, A.; Ponnudurai, R.; et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 2019, 25, 679–689. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gethings-Behncke, C.; Coleman, H.G.; Jordao, H.W.T.; Longley, D.B.; Crawford, N.; Murray, L.J.; Kunzmann, A.T. Fusobacterium nucleatum in the Colorectum and Its Association with Cancer Risk and Survival: A Systematic Review and Meta-analysis. Cancer Epidemiol. Biomark. Prev. 2020, 29, 539–548. [Google Scholar] [CrossRef] [Green Version]
- Hussan, H.; Clinton, S.K.; Roberts, K.; Bailey, M.T. Fusobacterium’s link to colorectal neoplasia sequenced: A systematic review and future insights. World J. Gastroenterol. 2017, 23, 8626–8650. [Google Scholar] [CrossRef]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 2009, 151, 264–269. [Google Scholar] [CrossRef] [Green Version]
- Wells, G.A.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: http://www.ohri.ca//programs/clinical_epidemiology/oxford.asp (accessed on 1 January 2021).
- Huybrechts, I.; Zouiouich, S.; Loobuyck, A.; Vandenbulcke, Z.; Vogtmann, E.; Pisanu, S.; Iguacel, I.; Scalbert, A.; Indave, I.; Smelov, V.; et al. The Human Microbiome in Relation to Cancer Risk: A Systematic Review of Epidemiologic Studies. Cancer Epidemiol. Biomark. Prev. 2020, 29, 1856–1868. [Google Scholar] [CrossRef]
- Geng, J.; Song, Q.; Tang, X.; Liang, X.; Fan, H.; Peng, H.; Guo, Q.; Zhang, Z. Co-occurrence of driver and passenger bacteria in human colorectal cancer. Gut Pathog. 2014, 6, 26. [Google Scholar] [CrossRef] [Green Version]
- Mira-Pascual, L.; Cabrera-Rubio, R.; Ocon, S.; Costales, P.; Parra, A.; Suarez, A.; Moris, F.; Rodrigo, L.; Mira, A.; Collado, M.C. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J. Gastroenterol. 2015, 50, 167–179. [Google Scholar] [CrossRef] [PubMed]
- Thomas, A.M.; Jesus, E.C.; Lopes, A.; Aguiar, S., Jr.; Begnami, M.D.; Rocha, R.M.; Carpinetti, P.A.; Camargo, A.A.; Hoffmann, C.; Freitas, H.C.; et al. Tissue-Associated Bacterial Alterations in Rectal Carcinoma Patients Revealed by 16S rRNA Community Profiling. Front. Cell Infect. Microbiol. 2016, 6, 179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, H.; Chang, Y.; Zheng, Q.; Zhang, R.; Hu, C.; Jia, W. Altered intestinal microbiota associated with colorectal cancer. Front. Med. 2019, 13, 461–470. [Google Scholar] [CrossRef] [PubMed]
- Allali, I.; Delgado, S.; Marron, P.I.; Astudillo, A.; Yeh, J.J.; Ghazal, H.; Amzazi, S.; Keku, T.; Azcarate-Peril, M.A. Gut microbiome compositional and functional differences between tumor and non-tumor adjacent tissues from cohorts from the US and Spain. Gut Microbes 2015, 6, 161–172. [Google Scholar] [CrossRef] [Green Version]
- Brim, H.; Yooseph, S.; Lee, E.; Sherif, Z.A.; Abbas, M.; Laiyemo, A.O.; Varma, S.; Torralba, M.; Dowd, S.E.; Nelson, K.E.; et al. A Microbiomic Analysis in African Americans with Colonic Lesions Reveals Streptococcus sp.VT162 as a Marker of Neoplastic Transformation. Genes 2017, 8, 314. [Google Scholar] [CrossRef] [Green Version]
- Burns, M.B.; Lynch, J.; Starr, T.K.; Knights, D.; Blekhman, R. Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. Genome Med. 2015, 7, 55. [Google Scholar] [CrossRef] [Green Version]
- Chen, W.; Liu, F.; Ling, Z.; Tong, X.; Xiang, C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE 2012, 7, e39743. [Google Scholar] [CrossRef]
- Cremonesi, E.; Governa, V.; Garzon, J.F.G.; Mele, V.; Amicarella, F.; Muraro, M.G.; Trella, E.; Galati-Fournier, V.; Oertli, D.; Däster, S.R.; et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut 2018, 67, 1984–1994. [Google Scholar] [CrossRef]
- de Carvalho, A.C.; de Mattos Pereira, L.; Datorre, J.G.; Dos Santos, W.; Berardinelli, G.N.; Matsushita, M.M.; Oliveira, M.A.; Durães, R.O.; Guimarães, D.P.; Reis, R.M. Microbiota Profile and Impact of Fusobacterium nucleatum in Colorectal Cancer Patients of Barretos Cancer Hospital. Front. Oncol. 2019, 9, 813. [Google Scholar] [CrossRef] [Green Version]
- Drewes, J.L.; White, J.R.; Dejea, C.M.; Fathi, P.; Iyadorai, T.; Vadivelu, J.; Roslani, A.C.; Wick, E.C.; Mongodin, E.F.; Loke, M.F.; et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. NPJ Biofilms Microbiomes 2017, 3, 34. [Google Scholar] [CrossRef] [Green Version]
- Gao, R.; Kong, C.; Huang, L.; Li, H.; Qu, X.; Liu, Z.; Lan, P.; Wang, J.; Qin, H. Mucosa-associated microbiota signature in colorectal cancer. Eur. J. Clin. Microbiol. Infect. Dis 2017, 36, 2073–2083. [Google Scholar] [CrossRef] [PubMed]
- Geng, J.; Fan, H.; Tang, X.; Zhai, H.; Zhang, Z. Diversified pattern of the human colorectal cancer microbiome. Gut Pathog. 2013, 5, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hale, V.L.; Jeraldo, P.; Mundy, M.; Yao, J.; Keeney, G.; Scott, N.; Cheek, E.H.; Davidson, J.; Greene, M.; Martinez, C.; et al. Synthesis of multi-omic data and community metabolic models reveals insights into the role of hydrogen sulfide in colon cancer. Methods 2018, 149, 59–68. [Google Scholar] [CrossRef]
- Kinross, J.; Mirnezami, R.; Alexander, J.; Brown, R.; Scott, A.; Galea, D.; Veselkov, K.; Goldin, R.; Darzi, A.; Nicholson, J.; et al. A prospective analysis of mucosal microbiome-metabonome interactions in colorectal cancer using a combined MAS 1HNMR and metataxonomic strategy. Sci. Rep. 2017, 7, 8979. [Google Scholar] [CrossRef] [Green Version]
- Leung, P.H.M.; Subramanya, R.; Mou, Q.; Lee, K.T.; Islam, F.; Gopalan, V.; Lu, C.T.; Lam, A.K. Characterization of Mucosa-Associated Microbiota in Matched Cancer and Non-neoplastic Mucosa From Patients With Colorectal Cancer. Front. Microbiol. 2019, 10, 1317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, C.J.; Zhang, Y.L.; Shang, Y.; Wu, B.; Yang, E.; Luo, Y.Y.; Li, X.R. Intestinal bacteria detected in cancer and adjacent tissue from patients with colorectal cancer. Oncol. Lett. 2019, 17, 1115–1127. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Loke, M.F.; Chua, E.G.; Gan, H.M.; Thulasi, K.; Wanyiri, J.W.; Thevambiga, I.; Goh, K.L.; Wong, W.F.; Vadivelu, J. Metabolomics and 16S rRNA sequencing of human colorectal cancers and adjacent mucosa. PLoS ONE 2018, 13, e0208584. [Google Scholar] [CrossRef]
- Pan, H.W.; Du, L.T.; Li, W.; Yang, Y.M.; Zhang, Y.; Wang, C.X. Biodiversity and richness shifts of mucosa-associated gut microbiota with progression of colorectal cancer. Res. Microbiol. 2020, 171, 107–114. [Google Scholar] [CrossRef]
- Saffarian, A.; Mulet, C.; Regnault, B.; Amiot, A.; Tran-Van-Nhieu, J.; Ravel, J.; Sobhani, I.; Sansonetti, P.J.; Pédron, T. Crypt- and Mucosa-Associated Core Microbiotas in Humans and Their Alteration in Colon Cancer Patients. mBio 2019, 10, e01315-19. [Google Scholar] [CrossRef] [Green Version]
- Sheng, Q.S.; He, K.X.; Li, J.J.; Zhong, Z.F.; Wang, F.X.; Pan, L.L.; Lin, J.J. Comparison of Gut Microbiome in Human Colorectal Cancer in Paired Tumor and Adjacent Normal Tissues. Onco Targets Ther. 2020, 13, 635–646. [Google Scholar] [CrossRef] [Green Version]
- Wang, Q.; Ye, J.; Fang, D.; Lv, L.; Wu, W.; Shi, D.; Li, Y.; Yang, L.; Bian, X.; Wu, J.; et al. Multi-omic profiling reveals associations between the gut mucosal microbiome, the metabolome, and host DNA methylation associated gene expression in patients with colorectal cancer. BMC Microbiol. 2020, 20, 83. [Google Scholar] [CrossRef] [PubMed]
- Wirth, U.; Garzetti, D.; Jochum, L.M.; Spriewald, S.; Kühn, F.; Ilmer, M.; Lee, S.M.L.; Niess, H.; Bazhin, A.V.; Andrassy, J.; et al. Microbiome Analysis from Paired Mucosal and Fecal Samples of a Colorectal Cancer Biobank. Cancers 2020, 12, 3702. [Google Scholar] [CrossRef] [PubMed]
- Zeller, G.; Tap, J.; Voigt, A.Y.; Sunagawa, S.; Kultima, J.R.; Costea, P.I.; Amiot, A.; Böhm, J.; Brunetti, F.; Habermann, N.; et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol. Syst. Biol. 2014, 10, 766. [Google Scholar] [CrossRef] [PubMed]
- Flemer, B.; Lynch, D.B.; Brown, J.M.; Jeffery, I.B.; Ryan, F.J.; Claesson, M.J.; O’Riordain, M.; Shanahan, F.; O’Toole, P.W. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 2017, 66, 633–643. [Google Scholar] [CrossRef] [PubMed]
- Gao, Z.; Guo, B.; Gao, R.; Zhu, Q.; Qin, H. Microbiota disbiosis is associated with colorectal cancer. Front. Microbiol. 2015, 6, 20. [Google Scholar] [CrossRef] [PubMed]
- Nakatsu, G.; Li, X.; Zhou, H.; Sheng, J.; Wong, S.H.; Wu, W.K.; Ng, S.C.; Tsoi, H.; Dong, Y.; Zhang, N.; et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat. Commun. 2015, 6, 8727. [Google Scholar] [CrossRef] [PubMed]
- Richard, M.L.; Liguori, G.; Lamas, B.; Brandi, G.; da Costa, G.; Hoffmann, T.W.; Pierluigi Di Simone, M.; Calabrese, C.; Poggioli, G.; Langella, P.; et al. Mucosa-associated microbiota dysbiosis in colitis associated cancer. Gut Microbes 2018, 9, 131–142. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Zhang, C.; Hou, S.; Wu, X.; Liu, J.; Wan, X. Analyses of Potential Driver and Passenger Bacteria in Human Colorectal Cancer. Cancer Manag. Res. 2020, 12, 11553–11561. [Google Scholar] [CrossRef]
- Choi, S.; Chung, J.; Cho, M.L.; Park, D.; Choi, S.S. Analysis of changes in microbiome compositions related to the prognosis of colorectal cancer patients based on tissue-derived 16S rRNA sequences. J. Transl. Med. 2021, 19, 485. [Google Scholar] [CrossRef] [PubMed]
- Liu, W.; Zhang, X.; Xu, H.; Li, S.; Lau, H.C.; Chen, Q.; Zhang, B.; Zhao, L.; Chen, H.; Sung, J.J.; et al. Microbial Community Heterogeneity Within Colorectal Neoplasia and its Correlation With Colorectal Carcinogenesis. Gastroenterology 2021, 160, 2395–2408. [Google Scholar] [CrossRef]
- Malik, S.A.; Zhu, C.; Li, J.; LaComb, J.F.; Denoya, P.I.; Kravets, I.; Miller, J.D.; Yang, J.; Kramer, M.; McCombie, W.R.; et al. Impact of preoperative antibiotics and other variables on integrated microbiome-host transcriptomic data generated from colorectal cancer resections. World J. Gastroenterol. 2021, 27, 1465–1482. [Google Scholar] [CrossRef] [PubMed]
- Nardelli, C.; Granata, I.; Nunziato, M.; Setaro, M.; Carbone, F.; Zulli, C.; Pilone, V.; Capoluongo, E.D.; De Palma, G.D.; Corcione, F.; et al. 16S rRNA of Mucosal Colon Microbiome and CCL2 Circulating Levels Are Potential Biomarkers in Colorectal Cancer. Int. J. Mol. Sci. 2021, 22, 747. [Google Scholar] [CrossRef] [PubMed]
- Niccolai, E.; Russo, E.; Baldi, S.; Ricci, F.; Nannini, G.; Pedone, M.; Stingo, F.C.; Taddei, A.; Ringressi, M.N.; Bechi, P.; et al. Significant and Conflicting Correlation of IL-9 With Prevotella and Bacteroides in Human Colorectal Cancer. Front. Immunol. 2020, 11, 573158. [Google Scholar] [CrossRef]
- Okuda, S.; Shimada, Y.; Tajima, Y.; Yuza, K.; Hirose, Y.; Ichikawa, H.; Nagahashi, M.; Sakata, J.; Ling, Y.; Miura, N.; et al. Profiling of host genetic alterations and intra-tumor microbiomes in colorectal cancer. Comput. Struct. Biotechnol. J. 2021, 19, 3330–3338. [Google Scholar] [CrossRef] [PubMed]
- Osman, M.A.; Neoh, H.M.; Ab Mutalib, N.S.; Chin, S.F.; Mazlan, L.; Raja Ali, R.A.; Zakaria, A.D.; Ngiu, C.S.; Ang, M.Y.; Jamal, R. Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer. Sci. Rep. 2021, 11, 2925. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Zhang, Y.; Qian, Y.; Xie, Y.H.; Jiang, S.S.; Kang, Z.R.; Chen, Y.X.; Chen, Z.F.; Fang, J.Y. Alterations in the oral and gut microbiome of colorectal cancer patients and association with host clinical factors. Int. J. Cancer 2021, 149, 925–935. [Google Scholar] [CrossRef]
- Zhang, J.; Tao, J.; Gao, R.N.; Wei, Z.Y.; He, Y.S.; Ren, C.Y.; Li, Q.C.; Liu, Y.S.; Wang, K.W.; Yang, G.; et al. Cytotoxic T-Cell Trafficking Chemokine Profiles Correlate With Defined Mucosal Microbial Communities in Colorectal Cancer. Front. Immunol. 2021, 12, 715559. [Google Scholar] [CrossRef]
- Tilg, H.; Kaser, A. Gut microbiome, obesity, and metabolic dysfunction. J. Clin. Investig. 2011, 121, 2126–2132. [Google Scholar] [CrossRef]
- Ahn, J.; Sinha, R.; Pei, Z.; Dominianni, C.; Wu, J.; Shi, J.; Goedert, J.J.; Hayes, R.B.; Yang, L. Human gut microbiome and risk for colorectal cancer. J. Natl. Cancer Inst. 2013, 105, 1907–1911. [Google Scholar] [CrossRef] [Green Version]
- Zhang, B.; Xu, S.; Xu, W.; Chen, Q.; Chen, Z.; Yan, C.; Fan, Y.; Zhang, H.; Liu, Q.; Yang, J. Leveraging fecal bacterial survey data to predict colorectal tumors. Front. Genet. 2019, 10, 447. [Google Scholar] [CrossRef] [Green Version]
- Yang, Y.; Misra, B.B.; Liang, L.; Bi, D.; Weng, W.; Wu, W.; Cai, S.; Qin, H.; Goel, A.; Li, X. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer. Theranostics 2019, 9, 4101. [Google Scholar] [CrossRef]
- Flanagan, L.; Schmid, J.; Ebert, M.; Soucek, P.; Kunicka, T.; Liska, V.; Bruha, J.; Neary, P.; Dezeeuw, N.; Tommasino, M. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33, 1381–1390. [Google Scholar] [CrossRef] [PubMed]
- Mima, K.; Nishihara, R.; Qian, Z.R.; Cao, Y.; Sukawa, Y.; Nowak, J.A.; Yang, J.; Dou, R.; Masugi, Y.; Song, M.; et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016, 65, 1973–1980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, T.; Guo, F.; Yu, Y.; Sun, T.; Ma, D.; Han, J.; Qian, Y.; Kryczek, I.; Sun, D.; Nagarsheth, N. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017, 170, 548–563.e516. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rubinstein, M.R.; Wang, X.; Liu, W.; Hao, Y.; Cai, G.; Han, Y.W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013, 14, 195–206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- He, Z.; Gharaibeh, R.Z.; Newsome, R.C.; Pope, J.L.; Dougherty, M.W.; Tomkovich, S.; Pons, B.; Mirey, G.; Vignard, J.; Hendrixson, D.R. Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. Gut 2019, 68, 289–300. [Google Scholar] [CrossRef] [Green Version]
- Abdulamir, A.S.; Hafidh, R.R.; Bakar, F.A. The association of Streptococcus bovis/gallolyticus with colorectal tumors: The nature and the underlying mechanisms of its etiological role. J. Exp. Clin. Cancer Res. 2011, 30, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Abdulamir, A.S.; Hafidh, R.R.; Bakar, F.A. Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: Inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol. Cancer 2010, 9, 1–18. [Google Scholar] [CrossRef] [Green Version]
- Edwards, A.M.; Grossman, T.J.; Rudney, J.D. Fusobacterium nucleatum transports noninvasive Streptococcus cristatus into human epithelial cells. Infect. Immun. 2006, 74, 654–662. [Google Scholar] [CrossRef] [Green Version]
- Warren, R.L.; Freeman, D.J.; Pleasance, S.; Watson, P.; Moore, R.A.; Cochrane, K.; Allen-Vercoe, E.; Holt, R.A. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome 2013, 1, 16. [Google Scholar] [CrossRef] [Green Version]
- Yu, J.; Zhao, L.; Zhao, R.; Long, X.; Coker, O.O.; Sung, J.J. The role of Parvimonas micra in intestinal tumorigenesis in germ-free and conventional APCmin/+ mice. J. Clin. Oncol. 2019, 37, 531. [Google Scholar] [CrossRef]
- Long, X.; Wong, C.C.; Tong, L.; Chu, E.S.; Ho Szeto, C.; Go, M.Y.; Coker, O.O.; Chan, A.W.; Chan, F.K.; Sung, J.J. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat. Microbiol. 2019, 4, 2319–2330. [Google Scholar] [CrossRef] [PubMed]
- Tsoi, H.; Chu, E.S.; Zhang, X.; Sheng, J.; Nakatsu, G.; Ng, S.C.; Chan, A.W.; Chan, F.K.; Sung, J.J.; Yu, J. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 2017, 152, 1419–1433.e1415. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boleij, A.; Hechenbleikner, E.M.; Goodwin, A.C.; Badani, R.; Stein, E.M.; Lazarev, M.G.; Ellis, B.; Carroll, K.C.; Albesiano, E.; Wick, E.C.; et al. The Bacteroides fragilis Toxin Gene Is Prevalent in the Colon Mucosa of Colorectal Cancer Patients. Clin. Infect. Dis. 2014, 60, 208–215. [Google Scholar] [CrossRef]
- Sanfilippo, L.; Li, C.; Seth, R.; Balwin, T.; Menozzi, M.; Mahida, Y. Bacteroides fragilis enterotoxin induces the expression of IL-8 and transforming growth factor-beta (TGF-β) by human colonic epithelial cells. Clin. Exp. Immunol. 2000, 119, 456–463. [Google Scholar] [CrossRef]
- Ferreira-Halder, C.V.; de Sousa Faria, A.V.; Andrade, S.S. Action and function of Faecalibacterium prausnitzii in health and disease. Best Pract. Res. Clin. Gastroenterol. 2017, 31, 643–648. [Google Scholar] [CrossRef]
- Zhang, M.; Qiu, X.; Zhang, H.; Yang, X.; Hong, N.; Yang, Y.; Chen, H.; Yu, C. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS ONE 2014, 9, e109146. [Google Scholar] [CrossRef] [Green Version]
- Koh, G.Y.; Kane, A.V.; Wu, X.; Crott, J.W. Parabacteroides distasonis attenuates tumorigenesis, modulates inflammatory markers and promotes intestinal barrier integrity in azoxymethane-treated A/J mice. Carcinogenesis 2020, 41, 909–917. [Google Scholar] [CrossRef]
- Liu, X.; Mao, B.; Gu, J.; Wu, J.; Cui, S.; Wang, G.; Zhao, J.; Zhang, H.; Chen, W. Blautia—A new functional genus with potential probiotic properties? Gut Microbes 2021, 13, 1875796. [Google Scholar] [CrossRef]
- Jones, S.; Chen, W.D.; Parmigiani, G.; Diehl, F.; Beerenwinkel, N.; Antal, T.; Traulsen, A.; Nowak, M.A.; Siegel, C.; Velculescu, V.E.; et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. USA 2008, 105, 4283–4288. [Google Scholar] [CrossRef] [Green Version]
- Zackular, J.P.; Baxter, N.T.; Iverson, K.D.; Sadler, W.D.; Petrosino, J.F.; Chen, G.Y.; Schloss, P.D. The gut microbiome modulates colon tumorigenesis. mBio 2013, 4, e00692-13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tjalsma, H.; Boleij, A.; Marchesi, J.R.; Dutilh, B.E. A bacterial driver–passenger model for colorectal cancer: Beyond the usual suspects. Nat. Rev. Microbiol. 2012, 10, 575–582. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, T.A.; Ley, R.E. The role of the microbiota in human genetic adaptation. Science 2020, 370, eaaz6827. [Google Scholar] [CrossRef]
- Knight, R.; Vrbanac, A.; Taylor, B.C.; Aksenov, A.; Callewaert, C.; Debelius, J.; Gonzalez, A.; Kosciolek, T.; McCall, L.I.; McDonald, D.; et al. Best practices for analysing microbiomes. Nat. Rev. Microbiol. 2018, 16, 410–422. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bukin, Y.S.; Galachyants, Y.P.; Morozov, I.V.; Bukin, S.V.; Zakharenko, A.S.; Zemskaya, T.I. The effect of 16S rRNA region choice on bacterial community metabarcoding results. Sci. Data 2019, 6, 190007. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Graf, D.; Di Cagno, R.; Fåk, F.; Flint, H.J.; Nyman, M.; Saarela, M.; Watzl, B. Contribution of diet to the composition of the human gut microbiota. Microb. Ecol. Health Dis. 2015, 26, 26164. [Google Scholar] [CrossRef] [PubMed]
First Author, Year | Country | No. Participants | Study Participants (Males) Age Mean or Median ± SD (Range) | Recruitment | Exclusions | |
---|---|---|---|---|---|---|
CRC | Healthy Controls | |||||
Geng, 2014 [33] | China | 18 | 8 (4) Mean 56.9 ± 14.4 | 10 (NR) NR | CRC: Undergoing colonoscopy HC: volunteers | NR |
Gao, 2015 [58] | China | 61 | 31 (15) Mean 67 ± 7.2 | 30 (14) Mean 70 ± 5.1 | CRC: Undergoing CRC surgery HC: Undergoing colonoscopy | HC: BMI > 30 kg/m2; HC and CRC: use of antibiotics within 2 months, regular use of NSAIDs, statins, or probiotics; chronic bowel disorders, food allergies/dietary restrictions; pre-operative radiation or chemotherapy |
Mira-Pascual, 2015 [34] | Spain | 12 | 7 (7) Mean 71.1 ± 10.1 | 5 (3) Mean 58.8 ± 10 | Undergoing CRC screening | NR |
Nakatsu, 2015 [59] | China | DC: 113 VC: 75 | DC: 52 (31) Mean 67.85 ± 13.18 VC: 50 (26) Mean 61.34 ± 9.97 | DC: 61 (25) Mean 60.813 ± 5.99 VC: 25 (10) Mean 41.28 ± 7.87 | Undergoing CRC screening | Personal history of CRC, IBD, prosthetic heart valve or vascular graft surgery; contraindications for colonoscopy |
Thomas, 2016 [35] | Brazil | 36 | 18 (10) Mean 59.3 ± 8.8 | 18 (9) Mean 55.2 ±15.7 | HC: Undergoing exploratory colonoscopy CRC: Undergoing CRC surgery | HC and CRC: use of antibiotics 4 weeks before sample collection; CRC: neoadjuvant therapy prior to tissue collection; IBD, hereditary cancer syndromes |
Flemer, 2017 [57] | Ireland | 115 | 59 (37) Range 41–90 | 56 (24) Range 27–29 | HC: Undergoing s colonoscopy CRC: Undergoing CRC surgery | HC and CRC: Personal history of CRC, IBD, or IBS; CRC: use of antibiotics the month prior to surgery |
Richard, 2018 [60] | Italy | 27 | CAC: 7(5) Mean 50.7 ± 10 SC: 10 (5) Mean 68.8 ± 12.1 | 10 (7) Mean 48.3 ± 13.4 | HC: Undergoing routine screening CRC: Undergoing CRC surgery | HC: History/clinical symptoms of intestinal disorders and endoscopic/histological signs of cancer or IBD; HC and CRC: Infectious colitis, coagulation disorders, anticoagulant therapy; use of antibiotics/antifungal therapy 2 months before inclusion |
Zhang, 2019 [36] | China | 23 | 9 (6) Mean 62.6 ± 8.9 | 14 (7) Mean 44.1 ± 15 | Undergoing CRC screening | IBS; use of antibiotics or probiotics 30 days or infectious gastroenteritis 60 days before colonoscopy |
Wang Y, 2020 [61] | China | 101 | 75 (48) Mean 63.4 (Range 29–82) | 26 (17) Mean 51.7 (Range 21–71) | HC: Undergoing colonoscopy CRC: Undergoing CRC surgery | NR |
Nardelli, 2021 [65] | Italy | 40 | 20 (10) Mean 69.4 | 20 (10) Mean 53.2 | HC: Undergoing colonoscopy CRC: Undergoing CRC surgery | IBD or IBS; use of antibiotics, pro/prebiotics, antiviral, or corticosteroids 2 months prior to sample collection |
Osman, 2021 [68] | Malaysia | 36 | 18 (12) Mean 64.88 ± 2.34 | 18 (11) Mean 54.44 ± 2.91 | Undergoing colonoscopy and tumor removal surgery | History of cancer, IBD and polyps; use of antibiotics 3 months prior to radiotherapy or chemotherapy prior to surgery |
Wang, 2021 [69] | China | 60 | 30 (17) Mean 63.9 ± 6.58 | 30 (15) Mean 52.17 ±9.02 | HC: Undergoing colonoscopy CRC: Undergoing surgery | History of cancer, Peutz–Jeghers or Lynch syndromes; use of antibiotics/NSAIDS 1 month prior to sample collection |
First Author, Year | Country | No. Participants (Males) | Age Mean ± SD Median (Range) | Recruitment | Exclusions | NCT Distance from Tumor |
---|---|---|---|---|---|---|
Marchesi, 2011 [19] | The Netherlands | 6 (5) | Mean 63.5 (49–71) | Undergoing CRC surgery | NR | 5–10 cm |
Chen, 2012 [40] | China | 46 (NR) For analysis: 27 (14) | Mean 61 (37–81) | Undergoing CRC surgery | Diabetes, infectious diseases, particular diets; use of antibiotics within 1 month of sample collection | Pa2t: 2–5 cm; Pa10t: 10–20 cm |
Geng, 2013 [45] | China | 8 (4) | Mean 56.9 ± 14.4 | Undergoing CRC screening | NR | NR |
Zeller, 2014 [56] | Germany | 38 (25) | Mean 61.7 ± 13.5 (34–90) | Undergoing CRC surgery | Previous colon or rectal surgery, CRC, inflammatory or infectious injuries of the intestine; need for emergency colonoscopy | NR |
Allali, 2015 [37] | USA Spain | USA: 22 (11) Spain: 23 (15) | Mean 63.6 (42–88) Mean 69.8 (49–85) | Tissue bank Undergoing CRC surgery | NR | USA: NR Spain: 5 cm |
Burns, 2015 [39] | USA | 44 (12) | Mean 64.9 ± 16.7 (17–91) | Biobank | NR | NR |
Gao, 2015 [58] | China | 31 (15) For analysis: 20 NCT | Mean 67 ± 7.2 | Undergoing CRC surgery | Use of antibiotics within 2 months, regular use of NSAIDs, statins, or probiotics; chronic bowel disorders, food allergies/dietary restrictions; pre-operative radiation or chemotherapy | 5 cm |
Nakatsu, 2015 [59] | China | DC: 52 (31) VC: 50 (26) | DC: Mean 67.85 ± 13.18 VC: Mean 61.34 ± 9.97 | Undergoing CRC screening | Personal history of CRC, IBD, prosthetic heart valve or vascular graft surgery; contraindications for colonoscopy | ≥4 cm |
Brim, 2017 [38] | USA | 10 (5) | Range 41–88 | Undergoing CRC surgery | NR | NR |
Drewes, 2017 [43] | Malaysia | 23 (12) | Mean 62.22 ± 11.99 | Undergoing CRC surgery | Personal history of CRC or IBD; pre-operative radiation or chemotherapy | NR (as far as possible) |
Flemer, 2017 [57] | Ireland | 59 (37) | Range 41–90 | Undergoing CRC surgery | Personal history of CRC, IBD, or IBS; use of antibiotics the month prior to surgery | OFFD and OFFP: 2–5 cm; UDD and UDP: 10–30 cm from the tumor |
Gao, 2017 [44] | China | 65 (35) | Mean 63.49 ± 1.46 | Undergoing CRC surgery | Use of antibiotics or probiotics within 4 weeks, acute diarrhea, adenoma or polyps, IBD, IBS | >5 cm |
Kinross, 2017 [47] | UK | 18 (10) | Median 76 (55–85) | Undergoing CRC surgery | Previous colorectal surgery, undergoing emergency surgery; pre-operative chemotherapy or radiotherapy; use of antibiotics or probiotics 6 weeks prior to surgery; history of FAP or IBD | 5 cm and 10 cm |
Cremonesi, 2018 [41] | Germany | 31 (21) For analysis: 27 | 67.5 (35–82) | Undergoing CRC surgery | NR | NR |
Hale, 2018 [46] | USA | 106 (57) | Mean 65.3 (23–90) | Undergoing CRC surgery | Radio or chemotherapy 2 weeks before enrollment | NR (adjacent and distal) |
Loke, 2018 [50] | Malaysia | 17 (7) | Mean 62.47 (41–84) | Undergoing CRC surgery | Pre-operative radiation or chemotherapy; history of CRC or IBD | NR |
Richard, 2018 [60] | Italy | CAC: 7(5) SC: 10 (5) | CAC: Mean 50.7 ± 10 SC: Mean 68.8 ± 12.1 | Undergoing CRC surgery | Infectious colitis, coagulation disorders, anti-coagulant therapy; use of antibiotics or antifungal therapy 2 months before inclusion | <5 cm |
de Carvalho, 2019 [42] | Brazil | 152 (81) For analysis: 15 | Mean 60.63 ± 13.7 | Undergoing CRC surgery | NR | NR |
Leung, 2019 [48] | Australia | 19 (9) | Mean 64.7 ± 15.4 | Undergoing CRC surgery | NR | Proximal resection margin |
Liu, 2019 [49] | China | 8 (5) | Mean 61.3 ± 10.1 (50–78) | Undergoing CRC surgery | NR | 2 cm |
Saffarian, 2019 [52] | France | 58 (37) | Mean 68.98 (23–92) | Undergoing CRC surgery | Undergoing chemotherapy, radiotherapy, or antibiotic treatment | 15–20 cm |
Pan, 2020 [51] | China | 23 (11) | Range: 49–70 | Undergoing CRC surgery | Use of antibiotics prior to sample collection | >5 cm |
Sheng, 2020 [53] | China | 66 (38) | Range: 35–94 | NR | Radiotherapy or chemotherapy before surgery; use of antibiotics, NSAIDs, statins, or probiotics 3 months before surgery; family history of CRC; IBD; diabetes; hypertension; food allergies | >10 cm |
Wang Q, 2020 [54] | China | 36 (NR) | NR | Undergoing CRC surgery | Use of antibiotics or probiotics 4 weeks before surgery; undergoing radiotherapy or chemotherapy; diabetes; infectious diseases | >5 cm |
Wang Y, 2020 [61] | China | 75 (48) | Mean 63.4 (29–82) | Undergoing CRC surgery | NR | Adjacent and off tumor |
Wirth, 2020 [55] | Germany | 6 (NR) | NR | Undergoing CRC surgery | NR | NR |
Choi, 2021 [62] | Republic of Korea | 51 (51) | Range: 43–86 | Undergoing CRC surgery | NR | NR |
Liu, 2021 [63] | China | DC: 11 (8) VC: 10 (8) | DC: Mean 64.91 ± 15.20 VC: Mean 65.33 ± 7.54 | NR | NR | NR |
Malik, 2021 [64] | USA | 51 (30) | 62 ± IQR 20 | Undergoing CRC surgery | Hereditary CRC syndromes, IBD; neoadjuvant treatment | NR |
Nardelli, 2021 [65] | Italy | 20 (10) | Mean 69.4 | Undergoing CRC surgery | IBD or IBS; use of antibiotics, pro/prebiotics, antivirals, or corticosteroids 2 months prior to sample collection | NR |
Niccolai, 2021 [66] | Italy | 45 (NR) | Range: 30–90 | Undergoing CRC surgery | Previous cancer surgery, chemo or radiotherapy; use of immunosuppressives, antibiotics, or probiotics in the previous 2 months; cancer, IBD | NR |
Okuda, 2021 [67] | Japan | 29 (15) | Range 37–94 | Underwent CRC surgery | CRC with FAP; IBD | 3 cm |
Zhang, 2021 [70] | China | 136 (81) For analysis 101 (58) | Median 64 (21–88) For analysis: Median 64 (21–88) | Undergoing CRC surgery | No chemo or radiotherapy and no antibiotics 1 month before resection | NR (as far as possible) |
α-Diversity | β-Diversity | |||
---|---|---|---|---|
First Author, Year | Measure | Findings in CRC | Measure | Findings |
Geng, 2014 [33] | NR | NR | NR | NR |
Gao, 2015 [58] | Shannon, Simpson, Chao1 and ACE indexes | Inconsistent between text description and figures | NR | NR |
Mira-Pascual, 2015 [34] | NR | NR | UniFrac | Distinguished CRC from HC ‡ |
Nakatsu, 2015 [59] | NR | NR | NR | NR |
Thomas, 2016 [35] | Observed species, Shannon and Simpson indexes | Significantly higher | Unweighted and weighted UniFrac; Bray–Curtis dissimilarity | Distinguished CRC from HC |
Flemer, 2017 [57] | NR | NR | Unweighted and weighted UniFrac; Spearman rank distance | Distinguished CRC from HC |
Richard, 2018 [60] | Chao1 index Observed species and Shannon index | NS Significantly lower in CAC | Bray–Curtis dissimilarity | Distinguished HC from SC and CAC Distinguished SC from CAC |
Zhang, 2019 [36] | Shannon and Chao1 indexes | NS | Unweighted UniFrac | Similar between CRC and HC ‡ |
Wang Y, 2020 [61] | NR | NR | NR | NR |
Nardelli, 2021 [65] | NR | NR | Weighted UniFrac | Distinguished CRC from HC |
Osman, 2021 [68] | NR | NR | Unweighted UniFrac | Distinguished CRC from HC ‡ |
Wang, 2021 [69] | Observed species, Shannon, Chao, and ACE indexes | Significantly lower | Weighted UniFrac | Distinguished CRC from HC ‡ |
α-Diversity | β-Diversity | |||
---|---|---|---|---|
First Author, Year | Measure | Findings in CRC | Measure | Finding |
Marchesi, 2011 [19] | NR | NR | Libshuff analysis | Distinguished CRC from NCT |
Chen, 2012 [40] | Shannon index Chao index | Significantly lower NS | Unweighted UniFrac | NS |
Geng, 2013 [45] | Observed species | NS | UniFrac | Distinguished CRC from NCT ‡ |
Zeller, 2014 [56] | NR | NR | NR | NR |
Allali, 2015 [37] | Phylogenetic diversity and observed species | NS | Unweighted UniFrac | NS |
Burns, 2015 [39] | Phylogenetic diversity, Shannon and Inverse Simpson’s indexes | Significantly higher | NR | NR |
Gao, 2015 [58] | NR | NR | NR | NR |
Nakatsu, 2015 [59] | Inverse Simpson’s index | NS | NR | NR |
Brim, 2017 [38] | NR | NR | NR | NR |
Drewes, 2017 [43] | NR | NR | NR | NR |
Flemer, 2017 [57] | NR | NR | Unweighted and weighted UniFrac; Spearman rank distance | NS |
Gao, 2017 [44] | ACE, Chao1, Shannon, and Simpson indexes | NS | Bray–Curtis dissimilarity | Distinguished CRC from NCT ‡ |
Kinross, 2017 [47] | Shannon index | NS | Bray–Curtis dissimilarity | NR |
Cremonesi, 2018 [41] | NR | NR | NR | NR |
Hale, 2018 [46] | Shannon index | Significantly lower | Unweighted and weighted UniFrac | Similar between CRC and NCT ‡ |
Loke, 2018 [50] | Observed species and Shannon index | Significantly lower | Unweighted UniFrac | Distinguished CRC from NCT |
Richard, 2018 [60] | Observed species, Chao1, and Shannon indexes | NS | Bray–Curtis dissimilarity | NS |
de Carvalho, 2019 [42] | Observed species, Chao1, Shannon indexes and Phylogenetic diversity | NS | Unweighted UniFrac | Similar between CRC and NCT ‡ |
Leung, 2019 [48] | Observed species, Chao1, Shannon, and Simpson | NS | Weighted UniFrac | NS |
Liu, 2019 [49] | OTU number, Chao1, ACE, Shannon, and Simpson | NR | Weighted UniFrac | Similar between CRC and NCT ‡ |
Saffarian, 2019 [52] | Chao1 index | Lower ‡ | Unweighted UniFrac | Similar between CRC and NCT ‡ |
Pan, 2020 [51] | Shannon index | Significantly lower in stage III | NR | NR |
Sheng, 2020 [53] | Observed species, Chao1, Shannon, and Simpson | NS | Bray–Curtis dissimilarity | Similar between CRC and NCT ‡ |
Wang Q, 2020 [54] | NR | NR | Unweighted UniFrac | Distinguished CRC from NCT |
Wang Y, 2020 [61] | NR | NR | NR | NR |
Wirth, 2020 [55] | Shannon and Simpson indexes Chao1 and ACE indexes | Significantly lower NS | Unweighted and weighted UniFrac | NS |
Choi, 2021 [62] | Shannon index and observed species | Significantly lower | Bray–Curtis dissimilarity | Distinguished CRC from NCT |
Liu, 2021 [63] | Chao1 and Shannon indexes | NS | Bray–Curtis dissimilarity | NS |
Malik, 2021 [64] | Observed species, Shannon and Evenness indexes | NS | Morisita–Horn dissimilarity | Distinguished CRC from NCT |
Nardelli, 2021 [65] | Shannon index | NS | NR | NR |
Niccolai, 2021 [66] | Chao1 and breakaway species richness Shannon index and Evenness | Significantly lower NS | NR | NR |
Okuda, 2021 [67] | NR | NR | NR | NR |
Zhang, 2021 [70] | Pielou’s evenness, Phylogenetic diversity, ACE, Chao, Shannon, and Simpson indexes | Significantly lower | Unweighted UniFrac | Similar between CRC and NCT ‡ |
Microbial Taxa | CRC vs. HC N (%) Studies * | Origin | CRC vs. NCT N (%) Studies ** | Origin | |||
---|---|---|---|---|---|---|---|
E | W | E | W | ||||
Phylum | Actinobacteria | 4 (14%) | 3 | 1 | |||
Bacteroidetes | 5 (17%) | 1 | 4 | ||||
Fusobacteria | 4 (40%) | 2 | 2 | 8 (28%) | 3 | 5 | |
Family | Fusobacteriaceae | 3 (10%) | 2 | 1 | |||
Porphyromonadaceae | 4 (14%) | 2 | 2 | ||||
Rikenellaceae | 4 (14%) | 2 | 2 | ||||
Ruminococcaceae | 7 (24%) | 5 | 2 | ||||
Genus | Acinetobacter | 3 (10%) | 2 | 1 | |||
Akkermansia | 3 (10%) | 2 | 1 | ||||
Bacillus | 3 (10%) | 3 | 0 | ||||
Bifidobacterium | 3 (10%) | 3 | 0 | ||||
Blautia | 3 (30%) | 2 | 1 | 4 (14%) | 1 | 3 | |
Campylobacter | 4 (40%) | 3 | 1 | 9 (31%) | 5 | 4 | |
Collinsella | 3 (10%) | 3 | 0 | ||||
Faecalibacterium | 5 (17%) | 3 | 2 | ||||
Fusobacterium | 6 (60%) | 4 | 2 | 19 (66%) | 10 | 9 | |
Gemella | 3 (10%) | 2 | 1 | ||||
Granulicatella | 3 (30%) | 2 | 1 | 3 (10%) | 2 | 1 | |
Klebsiella | 3 (30%) | 1 | 2 | ||||
Parabacteroides | 9 (31%) | 5 | 4 | ||||
Parvimonas | 4 (40%) | 3 | 1 | 8 (28%) | 6 | 2 | |
Peptostreptococcus | 5 (50%) | 4 | 1 | 6 (21%) | 5 | 1 | |
Propionibacterium | 3 (30%) | 2 | 1 | ||||
Pseudomonas | 5 (17%) | 4 | 1 | ||||
Ruminococcus | 6 (21%) | 3 | 3 | ||||
Selenomonas | 4 (14%) | 4 | 0 | ||||
Streptococcus | 3 (30%) | 2 | 1 | 7 (24%) | 4 | 3 | |
Species | Bacteroides fragilis | 4 (40%) | 2 | 2 | 3 (10%) | 2 | 1 |
Faecalibacterium prausnitzii | 3 (10%) | 0 | 3 | ||||
Fusobacterium nucleatum | 3 (10%) | 1 | 2 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Costa, C.P.d.; Vieira, P.; Mendes-Rocha, M.; Pereira-Marques, J.; Ferreira, R.M.; Figueiredo, C. The Tissue-Associated Microbiota in Colorectal Cancer: A Systematic Review. Cancers 2022, 14, 3385. https://doi.org/10.3390/cancers14143385
Costa CPd, Vieira P, Mendes-Rocha M, Pereira-Marques J, Ferreira RM, Figueiredo C. The Tissue-Associated Microbiota in Colorectal Cancer: A Systematic Review. Cancers. 2022; 14(14):3385. https://doi.org/10.3390/cancers14143385
Chicago/Turabian StyleCosta, Carolina Pinto da, Patrícia Vieira, Melissa Mendes-Rocha, Joana Pereira-Marques, Rui Manuel Ferreira, and Ceu Figueiredo. 2022. "The Tissue-Associated Microbiota in Colorectal Cancer: A Systematic Review" Cancers 14, no. 14: 3385. https://doi.org/10.3390/cancers14143385